Pirfenidone facilitates immune infiltration and enhances the antitumor efficacy of PD-L1 blockade in mice

Idiopathic pulmonary fibrosis (IPF) patients have a high risk of developing lung cancer, with few treatment options available. Pirfenidone, an antifibrotic agent approved for the treatment of IPF, has been demonstrated to suppress the TGFβ signaling and modulate the expression of immune-related gene...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Oncoimmunology
Autores principales: Qin, Wan, Zou, Jun, Huang, Yongbiao, Liu, Chaofan, Kang, Yalin, Han, Hu, Tang, Yang, Li, Long, Liu, Bo, Zhao, Weiheng, Yuan, Xianglin
Formato: Artigo
Lenguaje:Inglês
Publicado: Taylor & Francis 2020
Materias:
Original Research
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC7781712/
https://ncbi.nlm.nih.gov/pubmed/33457101
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/2162402X.2020.1824631
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares